Samantha K. Millard

Samantha K. Millard

Auto-generated profile, based on publicly available information

Samantha K. Millard

Faculty of Medicine, University of New South Wales (UNSW)

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2022 in The Journal of Pain
Verified
Journal Article
Closed access
NCNahian S Chowdhury
Nahian S Chowdhury
WCWei-Ju Chang
Wei-Ju Chang
SMSamantha K. Millard
Samantha K. Millard
PSPatrick Skippen
Patrick Skippen
KBKatarzyna Bilska
Katarzyna Bilska
SSSiobhan Schabrun
Siobhan Schabrun

4 April 2022 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
SMSamantha K. Millard
Samantha K. Millard
AFAndrew Joshua Furman
Andrew Joshua Furman
AKAmy Kerr
Amy Kerr
DSDavid A. Seminowicz
David A. Seminowicz
FGFang Gao
Fang Gao
AMAli Mazaheri
Ali Mazaheri

26 July 2024 in Pain
Verified
Journal Article
Open access
YQYann Quide
Yann Quide
NJNeda Jahanshad
Neda Jahanshad
JAJamila Andoh
Jamila Andoh
GAGeorgia Antoniou
Georgia Antoniou
AAApkar Vania Apkarian
Apkar Vania Apkarian
SGSylvia M. Gustin
Sylvia M. Gustin

23 May 2024 in European Journal of Neuroscience
Verified
Journal Article
Open access
SMSamantha K. Millard
Samantha K. Millard
DSDarrah B. Speis
Darrah B. Speis
PSPatrick Skippen
Patrick Skippen
ACAlan K. I. Chiang
Alan K. I. Chiang
WCWei-Ju Chang
Wei-Ju Chang
SSSiobhan Schabrun
Siobhan Schabrun
Peak alpha frequency (PAF), the dominant oscillatory frequency within the alpha range (8–12 Hz), is associated with cognitive function and several neurological conditions, including chronic pain. Manipulating PAF could offer valuable insight into the relationship between PAF and various functions and conditions, potentially providing new treatment avenues. This systematic review aimed to comprehensively synthesise effects of non‐invasive brain stimulation (NIBS) on PAF speed. Relevant studies assessing PAF pre‐ and post‐NIBS in healthy adults were identified through systematic searches of electronic databases (Embase, PubMed, PsychINFO, Scopus, The Cochrane Library) and trial registers. The Cochrane risk‐of‐bias tool was employed for assessing study quality. Quantitative analysis was conducted through pairwise meta‐analysis when possible; otherwise, qualitative synthesis was performed. The review protocol was registered with PROSPERO (CRD42020190512) and the Open Science Framework (https://osf.io/2yaxz/). Eleven NIBS studies were included, all with a low risk‐of‐bias, comprising seven transcranial alternating current stimulation (tACS), three repetitive transcranial magnetic stimulation (rTMS), and one transcranial direct current stimulation (tDCS) study. Meta‐analysis of active tACS conditions (eight conditions from five studies) revealed no significant effects on PAF (mean difference [MD] = −0.12, 95% CI = −0.32 to 0.08, p = 0.24). Qualitative synthesis provided no evidence that tDCS altered PAF and moderate evidence for transient increases in PAF with 10 Hz rTMS. However, it is crucial to note that small sample sizes were used, there was substantial variation in stimulation protocols, and most studies did not specifically target PAF alteration. Further studies are needed to determine NIBS's potential for modulating PAF.

15 November 2023 in eLife
Verified
Journal Article
Open access
NCNahian S Chowdhury
Nahian S Chowdhury
ACAlan Ki Chiang
Alan Ki Chiang
SMSamantha K Millard
Samantha K Millard
PSPatrick Skippen
Patrick Skippen
WCWei-Ju Chang
Wei-Ju Chang
SSSiobhan M Schabrun
Siobhan M Schabrun
Transcranial magnetic stimulation (TMS) has been used to examine inhibitory and facilitatory circuits during experimental pain and in chronic pain populations. However, current applications of TMS to pain have been restricted to measurements of motor evoked potentials (MEPs) from peripheral muscles. Here, TMS was combined with electroencephalography (EEG) to determine whether experimental pain could induce alterations in cortical inhibitory/facilitatory activity observed in TMS-evoked potentials (TEPs). In Experiment 1 (n=29), multiple sustained thermal stimuli were administered to the forearm, with the first, second, and third block of thermal stimuli consisting of warm but non-painful (pre-pain block), painful (pain block) and warm but non-painful (post-pain block) temperatures, respectively. During each stimulus, TMS pulses were delivered while EEG (64 channels) was simultaneously recorded. Verbal pain ratings were collected between TMS pulses. Relative to pre-pain warm stimuli, painful stimuli led to an increase in the amplitude of the frontocentral negative peak ~45 ms post-TMS (N45), with a larger increase associated with higher pain ratings. Experiments 2 and 3 (n=10 in each) showed that the increase in the N45 in response to pain was not due to changes in sensory potentials associated with TMS, or a result of stronger reafferent muscle feedback during pain. This is the first study to use combined TMS-EEG to examine alterations in cortical excitability in response to pain. These results suggest that the N45 TEP peak, which indexes GABAergic neurotransmission, is implicated in pain perception and is a potential marker of individual differences in pain sensitivity.

1 July 2020 in Pain Reports
Verified
Journal Article
Open access
DSDavid A. Seminowicz
David A. Seminowicz
KBKatarzyna Bilska
Katarzyna Bilska
NCNahian S. Chowdhury
Nahian S. Chowdhury
PSPatrick Skippen
Patrick Skippen
SMSamantha K. Millard
Samantha K. Millard
SSSiobhan Schabrun
Siobhan Schabrun
Introduction: Temporomandibular disorder is a common musculoskeletal pain condition with development of chronic symptoms in 49% of patients. Although a number of biological factors have shown an association with chronic temporomandibular disorder in cross-sectional and case control studies, there are currently no biomarkers that can predict the development of chronic symptoms. The PREDICT study aims to undertake analytical validation of a novel peak alpha frequency (PAF) and corticomotor excitability (CME) biomarker signature using a human model of the transition to sustained myofascial temporomandibular pain (masseter intramuscular injection of nerve growth factor [NGF]). This article describes, a priori, the methods and analysis plan. Methods: This study uses a multisite longitudinal, experimental study to follow individuals for a period of 30 days as they progressively develop and experience complete resolution of NGF-induced muscle pain. One hundred fifty healthy participants will be recruited. Participants will complete twice daily electronic pain diaries from day 0 to day 30 and undergo assessment of pressure pain thresholds, and recording of PAF and CME on days 0, 2, and 5. Intramuscular injection of NGF will be given into the right masseter muscle on days 0 and 2. The primary outcome is pain sensitivity. Perspective: PREDICT is the first study to undertake analytical validation of a PAF and CME biomarker signature. The study will determine the sensitivity, specificity, and accuracy of the biomarker signature to predict an individual's sensitivity to pain. Registration details: ClinicalTrials.gov: NCT04241562 (prospective).